Natixis Advisors LLC Has $9.17 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Key Points

• Natixis Advisors LLC increased its investment in Halozyme Therapeutics by 20.4%, holding 143,745 shares valued at approximately $9.17 million as of the latest quarter.
• Halozyme Therapeutics reported a quarterly earnings per share of $1.11, exceeding analysts' expectations and showing a 35.2% year-over-year revenue growth to $264.86 million.
• Despite positive performance, analyst ratings are mixed, with the stock receiving an average rating of "Hold" and a consensus price target of $62.70.

Natixis Advisors LLC grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 20.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 143,745 shares of the biopharmaceutical company's stock after purchasing an additional 24,311 shares during the period. Natixis Advisors LLC owned about 0.12% of Halozyme Therapeutics worth $9,172,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bessemer Group Inc. lifted its stake in Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares in the last quarter. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter valued at about $29,000. Park Place Capital Corp grew its position in shares of Halozyme Therapeutics by 20.1% in the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after purchasing an additional 182 shares during the last quarter. UMB Bank n.a. grew its stake in shares of Halozyme Therapeutics by 267.4% in the first quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company's stock valued at $84,000 after acquiring an additional 960 shares in the last quarter. Finally, CWM LLC grew its stake in shares of Halozyme Therapeutics by 46.3% in the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company's stock valued at $88,000 after acquiring an additional 438 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Price Performance

HALO traded up $0.94 during trading on Friday, reaching $63.04. 882,654 shares of the stock were exchanged, compared to its average volume of 1,950,857. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $70.50. The company has a market capitalization of $7.77 billion, a price-to-earnings ratio of 14.42, a P/E/G ratio of 0.42 and a beta of 1.17. The business's 50 day moving average price is $55.84 and its two-hundred day moving average price is $57.88. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.30.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%. The company had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. During the same quarter in the prior year, the business earned $0.91 earnings per share. The company's revenue was up 40.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HALO. JPMorgan Chase & Co. raised their price objective on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a report on Thursday. Morgan Stanley raised shares of Halozyme Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $62.00 to $75.00 in a research report on Wednesday. Benchmark downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They set a "neutral" rating and a $55.00 price objective on the stock. Finally, Leerink Partners lowered shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a research report on Tuesday, May 13th. Two analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $66.56.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total transaction of $1,128,600.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $41,403,763.17. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders sold 60,000 shares of company stock worth $3,262,400. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.